A strengthened presence in biotechnologies

Genzyme discovers and delivers innovative treatments for patients like Sandra, who live with a rare disease. In 2011, Sanofi set its sights on finalizing the integration of Genzyme and creating a strong management team.

A new player in the field of multiple sclerosis, Genzyme’s portfolio includes two molecular entities*, alemtuzumab and teriflunomide, for which the marketing authorization applications were submitted in the United States in 2011 and in Europe in early 2012. Both treatments are for patients with relapsing multiple sclerosis.

* Definition p44 annual review

Read more